Daiichi Sankyo appoints Sunjin Lee to head Enhertu BU
By Eo, Yun-Ho | translator Alice Kang
24.12.16 05:28:52
가나다라
0
Company makes new appointments...appoints a tough industry veteran who served various positions at Baxter, Boehringer Ingelheim, etc.
Has launched multiple products while leading Takeda’s Oncology BU
▲Sunjin Lee, head of Enhertu BU, Daiichi Sankyo Korea
Daiichi Sankyo Korea has appointed Sunjin Lee (47), a former executive director of Takeda Pharmaceuticals Korea, as the new head of Daiichi Sankyo. According to industry sources, Daiichi Sankyo recently made the appointment. Lee will succeed Mr. Hyun-Joo Lee (48), who has left to head ZP Therapeutics Korea.
After working at Baxter Korea and Boehringer Ingelheim Korea, Lee joined Takeda in 2017 as the Marketing Manager of Takeda's Hemophilia Business Unit, where she developed creative marketing strategies.
At the company, Lee was recognized for her leadership skills, playing a pivotal role in improving access and awareness of Takeda's hemophilia business.
Eo, Yun-Ho(unkindfish@dailypharm.com)
If you want to see the full article, please JOIN US (click)